Obesity and Cancer: Why Fat Tissue Is More Than Storage
Excess body fat raises the risk of more than a dozen cancers. The reason has a lot to do with the fact that fat tissue behaves like a hormone-producing organ.
Most people think of body fat as inert padding — a place calories get parked. It isn't. Fat tissue is metabolically active, and in excess it shifts the body's hormonal environment in ways that, over time, raise the risk of cancer. The connection is one of the most consistent findings in modern cancer epidemiology, and the biology behind it is worth understanding.
The epidemiology is strong
A landmark prospective study of more than 900,000 U.S. adults found that higher body weight was associated with higher death rates from a broad range of cancers, leading the authors to estimate that excess weight could account for a meaningful share of cancer deaths [1]. Later work sharpened the picture. A large meta-analysis quantified how rising body mass index tracks with the incidence of many specific cancers [2], and in 2016 an International Agency for Research on Cancer working group reviewed the accumulated evidence and concluded there was sufficient basis to link the absence of excess body fat with lower risk for thirteen different cancers, including cancers of the breast (after menopause), colon, endometrium, kidney, pancreas, and esophagus [3].
Fat as an endocrine organ
The mechanistic explanation starts with a shift in thinking that took hold in the early 2000s: adipose tissue is an endocrine organ — that is, it secretes hormones and signaling molecules into the bloodstream, collectively called adipokines [4]. When fat mass grows, the mix and quantity of these signals change, and several of those changes happen to favor cancer growth.
A few of the main threads:
Hormones. Fat tissue contains an enzyme called aromatase that converts androgens into estrogen. More fat means more estrogen production, which helps explain the link between obesity and hormone-sensitive cancers such as postmenopausal breast and endometrial cancer.
Insulin and IGF-1. Excess fat drives insulin resistance, and the body compensates by keeping insulin levels chronically high. Insulin and a related molecule, insulin-like growth factor 1 (IGF-1), are growth signals — useful in the right context, but a persistent excess can encourage cells to keep dividing and discourage them from dying off as they should.
Inflammation. Enlarged fat tissue tends to be mildly but chronically inflamed, releasing cytokines that create an environment in which damaged cells are more likely to survive and proliferate.
Adiponectin. One protective adipokine, adiponectin, actually falls as fat mass rises, removing a brake that normally helps restrain abnormal cell growth.
None of these acts alone. Together they describe how surplus fat tilts the body toward a pro-growth, pro-inflammatory state.
What it means in practice
This isn't a reason for alarm so much as a reason that metabolic health is worth taking seriously. The same excess fat and high insulin that show up in diabetes risk are part of the cancer-risk story too, which means the things that improve one — losing excess fat, lowering insulin, reducing inflammation — plausibly help with the other. Risk is about probability, not destiny, and much of it is modifiable.
See how our metabolic program works
References
- Calle EE, et al. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003. PMID: 12711737
- Renehan AG, et al. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet. 2008. PMID: 18280327
- Lauby-Secretan B, et al. Body fatness and cancer — viewpoint of the IARC Working Group. N Engl J Med. 2016. PMID: 27557308
- Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab. 2004. PMID: 15181022